Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to establish a multi-center, retrospective database for patients with intramedullary spinal cord metastases (ISCM) and analyse the functional outcome in surgically treated ISCM patients. The hypothesis is that the surgical treatment of selected ISCM patients does not lead to persistent morbidity and does not increase mortality, compared to patients that are treated non-operatively. Secondary objectives are to assess pre- to postoperative neurological deficits, ambulatory status, and overall survival of surgically treated ISCM patients. The investigators intend to include a control cohort of patients with ISCM from participating centers, who underwent non-surgical oncological treatment (radiotherapy with or without chemotherapy). This control cohort of patients will be used to match patients with and without surgical treatment. Primary endpoint (analysed in surgically treated ISCM patients): Functional outcome at 90 days after treatment initiation, measured by the modified McCormick Scale. This is a score for grading of neurological function in spinal cord conditions. The McCormick scale ranges from Grade I (neurologically intact) to grade V (paraplegic or quadriplegic). The McCormick scale is suitable for our retrospective study because of its good reproducibility and comparability. Secondary endpoints (analysed in surgically treated ISCM patients and analysed in matched patients with and without surgical treatment): - Functional outcome by the McCormick scale and the modified Japanese Orthopaedic Association scale (mJOA) at 6 and 12 months. This is a score evaluating motor function of upper and lower extremities, sensory function of upper extremities and sphincter function / voidance. The mJOA ranges from 0 - 18 points, with higher score values representing better functional outcome. The minimum clinically important difference of the mJOA is 1-2 points, and scores lower than 14 indicate moderate myelopathy, scores lower than 11 indicate severe myelopathy. - Ambulatory status and continence at 90 days, 6 & 12 months (determined by mJOA subscores) - Neurological outcome, measured by American Spinal Cord Injury Association (ASIA) - Impairment Scale at 90 days, 6 and 12 months - Rate & type of complications at 90 days after treatment according to The Novel Therapy - Disability-Neurology Grade (TDN grade)16 - Overall survival (in days)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06042946
Study type Observational
Source Cantonal Hospital of St. Gallen
Contact Martin N. Stienen, PD, MD
Phone +41 71 494 2183
Email martin.stienen@kssg.ch
Status Recruiting
Phase
Start date September 1, 2023
Completion date July 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05059379 - Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer Phase 3
Recruiting NCT06197581 - Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer N/A
Completed NCT04321187 - Influence of Prostate Cancer Radiation on Aging
Terminated NCT03553212 - Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy N/A
Completed NCT02979691 - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 Phase 2/Phase 3
Terminated NCT03720158 - Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients N/A
Not yet recruiting NCT05339581 - IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation N/A
Recruiting NCT05308732 - Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy Phase 1
Recruiting NCT06313450 - De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma N/A
Active, not recruiting NCT03893461 - Coagulation System In STereotactic Radiotherapy Of NSCLC
Active, not recruiting NCT03475186 - Testing Ramipril to Prevent Memory Loss in People With Glioblastoma Phase 2
Recruiting NCT06418113 - Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma Phase 1
Recruiting NCT04819685 - Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury Phase 4
Completed NCT04783818 - Adjuvant Radiotherapy's Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction
Completed NCT04854525 - Breast Reconstruction in Previously Irradiated Breast
Completed NCT03226925 - Mechanically-assisted Ventilation in the Treatment of Moving Tumours With Photon and Proton Therapies N/A
Recruiting NCT04901234 - Adaptive RadioTherapy for OroPharynx Cancer Phase 2
Recruiting NCT06272617 - Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer N/A
Not yet recruiting NCT05561634 - Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Phase 2
Not yet recruiting NCT03168048 - Oncologic Therapy Support Via Means of a Dedicated Mobile App N/A